FUS and sarcoma: We here describe the clinical and histopathologic characteristics of sarcomas with FUS/EWSR1-TFCP2 fusions, which were categorized as spindle cell/sclerosing RMS in the most recent WHO classification, provide a comprehensive multi-omics portrait of these tumors, including two benign precursor lesions, and present the oncogenic properties and associated therapeutic vulnerabilities of underlying genetic alterations.